Immune Defense Protein Impact On Respiratory Immune Outcomes

Inclusion Criteria

• Age 60 years and older
• Individuals who experience upper respiratory symptoms (e.g. coughing, sneezing, congestion) at least 2-3 times during the cold/flu season.
• Able to read and understand English.
• Able to read, understand, and provide informed consent.
• Able to use a personal smartphone device and download Chloe by People Science.
• Able to receive shipment of the product at an address within the United States.

Exclusion Criteria

Any potential participants who

• Do not have a personal smartphone, internet access, or unwilling to download Chloe.
• Already in an immunocompromised state, including:

A. Infectious Causes

• HIV/AIDS
• Chronic hepatitis B or C (advanced stages)
• Tuberculosis (especially disseminated or extrapulmonary TB) B. Cancer-Related
• Leukemia (e.g., AML, ALL, CLL)
• Lymphoma (e.g., Hodgkin's and Non-Hodgkin's)
• Multiple Myeloma
• Any metastatic cancer receiving chemotherapy

C. Immunosuppressive Therapy:

Participants on

• Corticosteroids (e.g., ≥20 mg/day of prednisone for ≥2 weeks)
• Biologics (e.g., TNF inhibitors like infliximab, adalimumab)
• Calcineurin inhibitors (e.g., tacrolimus, cyclosporine)
• mTOR inhibitors (e.g., sirolimus)
• JAK inhibitors (e.g., tofacitinib)
• Chemotherapy or radiation therapy
• Anti-rejection meds post-organ transplant D. Transplant Patients
• Solid organ transplant (kidney, liver, heart, lung)
• Hematopoietic stem cell transplant (HSCT) E. Autoimmune or Inflammatory Diseases (especially when treated with immunosuppressants)
• Rheumatoid Arthritis
• Systemic Lupus Erythematosus (SLE)
• Psoriasis or Psoriatic Arthritis
• Inflammatory Bowel Disease (Crohn's disease, Ulcerative colitis)
• Multiple Sclerosis (especially on disease-modifying therapies)
• Other Concomitant Conditions and Therapies:

• Any investigational therapies or treatments within 30 days prior to enrollment.
• Known diagnosis of Asthma and/or COPD
• Currently diagnosed with Alcohol Use Disorder and/or Substance Use Disorder
• Any underlying medical conditions or comorbidities that may confound the evaluation of the study outcomes
• Have a significant illness, disease or condition which, in the opinion of the principal investigator, may impact their ability to participate in the study or impact the study outcomes
• Use of cannabis-containing products daily
• Use of nicotine-containing products daily
• Known hypersensitivity or previous allergic reaction to milk products, Sorbitol and/or tabletting aids.
• Are unlikely for any reason to be able to comply with the trial or considered unsuited for participation in the study by the Principal Investigator.